Phase II and phase III failures: 2013–2015

This article analyses recent data on the reported causes of drug candidate attrition, which indicate that lack of efficacy is the reason for approximately half of all phase II and phase III failures.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2016-12, Vol.15 (12), p.817-818
1. Verfasser:	Harrison, Richard K.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/109 631/154/2426 692/308/153 Biomedicine Biotechnology Cancer Research Clinical trials Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Forecasts and trends from-the-analysts-couch Humans Medicinal Chemistry Molecular Medicine Pharmaceutical research Pharmacology/Toxicology Treatment Failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This article analyses recent data on the reported causes of drug candidate attrition, which indicate that lack of efficacy is the reason for approximately half of all phase II and phase III failures.
ISSN:	1474-1776 1474-1784
DOI:	10.1038/nrd.2016.184